Hydroxyurea in Kenya

Product Description

Product Summary

Hydroxyurea (hydroxycarbamide) is a prescription medication used for:

• Sickle Cell Disease (SCD): Reduces painful crises, acute chest syndrome, and transfusion needs.
• Cancer: Chronic myeloid leukemia (CML), essential thrombocythemia, and polycythemia vera.
  Available as 500mg capsules in Kenya, it requires strict medical supervision due to myelosuppression risks.

Key Uses in Kenya

1. Sickle Cell Disease (Primary Indication)

• Mechanism: Increases fetal hemoglobin (HbF), reducing sickling of red blood cells.
• Benefits:
  • 50% reduction in pain crises.
  • Lowers stroke risk in children.
  • Improves survival and quality of life.
• Dosing:
  • Adults: Start at 15–20 mg/kg/day; max 35 mg/kg/day.
  • Children: 15–20 mg/kg/day (weight-based).

2. Oncology

• CML: 500mg twice daily (monitor blood counts).
• Essential Thrombocythemia: 500mg daily (adjust based on platelet count).

Composition

• Active Ingredient: Hydroxyurea 500mg per capsule.
• Form: Hard gelatin capsules (white/white).
• Inactive Ingredients: Lactose, magnesium stearate, gelatin.

How to Use

Critical Administration Rules

• Dosing:
  • SCD: Take once daily with water.
  • Cancer: May require divided doses.
• Hydration: Drink 2–3L water daily to reduce renal toxicity.
• Monitoring:
  • Blood Tests: CBC every 2–4 weeks (target ANC >2,000/µL, platelets >80,000/µL).
  • Renal/Liver Function: Every 3 months.

Renal/Hepatic Adjustment

Potential Side Effects

Common

• Myelosuppression (neutropenia, thrombocytopenia, anemia).
• Nausea, vomiting, diarrhea.
• Skin/nail changes (hyperpigmentation, ulcers).

Serious Risks

• Severe Myelosuppression:
  • Symptoms: Fever, chills, uncontrolled bleeding (emergency).
  • Action: Stop drug immediately; hospitalize for supportive care.
• Secondary Malignancies: Long-term use may increase leukemia risk (rare in SCD).
• Pancreatitis/Hepatotoxicity: Monitor amylase/LFTs.
• Leg Ulcers: Especially in SCD patients with history of ulcers.

Precautions & Interactions

Avoid if:

• Severe bone marrow suppression (ANC <1,500/µL, platelets <100,000/µL).
• Pregnancy (teratogenic – use contraception).
• Hypersensitivity to hydroxyurea.

Drug Interactions

• Myelosuppressive Agents (e.g., chemotherapy): Additive toxicity.
• Live Vaccines: Avoid (immunosuppression risk).
• Antiretrovirals (e.g., didanosine): Increased pancreatitis risk.

Pregnancy/Breastfeeding

• Category D: Avoid pregnancy (causes fetal malformations).
• Breastfeeding: Contraindicated (excreted in milk).

Frequently Asked Questions

1. Is hydroxyurea available over-the-counter in Kenya?
   No – prescription-only. Available at Kenyatta National Hospital, Moi Teaching & Referral Hospital, and specialized pharmacies.

2. How much does it cost?
   ~KES 2,000–5,000 per 500mg capsule. Monthly cost (SCD): ~KES 12,000–30,000.
   NHIF Coverage: Partial for SCD (requires pre-approval).

3. Why use it for sickle cell?
   It’s the only FDA-approved disease-modifying therapy for SCD. Reduces hospitalizations by 40%.

4. Can children take it?
   Yes – safe for children ≥9 months (dose adjusted by weight).

5. What if I miss a dose?
   Take when remembered unless near next dose. Never double-dose.

6. Are there Kenyan alternatives for SCD?
   L-glutamine (Endari) and crizanlizumab (Adakveo) are newer but less accessible.

7. Does it cure sickle cell?
   No – it manages symptoms and reduces complications.